Ardelyx - ARDX Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARDX shares.
View ARDX analyst ratings or view top-rated stocks.

4 brokers have issued 12-month price targets for Ardelyx's stock. Their ARDX share price forecasts range from $3.00 to $8.00. On average, they predict the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 47.8% from the stock's current price.
View analysts price targets for ARDX or view top-rated stocks among Wall Street analysts.

Ardelyx's stock was trading at $2.85 at the beginning of 2023. Since then, ARDX shares have increased by 42.5% and is now trading at $4.06.
View the best growth stocks for 2023 here.

Ardelyx saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 10,990,000 shares, an increase of 8.7% from the February 13th total of 10,110,000 shares. Based on an average trading volume of 7,590,000 shares, the short-interest ratio is currently 1.4 days.
View Ardelyx's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our ARDX earnings forecast.

Ardelyx, Inc. (NASDAQ:ARDX) released its quarterly earnings data on Friday, November, 12th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.07. The biopharmaceutical company had revenue of $1.17 million for the quarter, compared to analyst estimates of $0.85 million. Ardelyx had a negative trailing twelve-month return on equity of 95.19% and a negative net margin of 128.85%.

ETFs with the largest weight of Ardelyx (NASDAQ:ARDX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), Invesco Nasdaq Biotechnology ETF (IBBQ) and ProShares Ultra Nasdaq Biotechnology (BIB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD) and Advanced Micro Devices (AMD).

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Ardelyx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Orchard Capital Management LLC (1.46%), Two Sigma Investments LP (1.18%), Price T Rowe Associates Inc. MD (1.16%), Lion Point Capital LP (0.95%), Geode Capital Management LLC (0.87%) and Pekin Hardy Strauss Inc. (0.84%). Insiders that own company stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends.

Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARDX stock can currently be purchased for approximately $4.06.

Ardelyx (NASDAQ:ARDX) has a market capitalization of $838.36 million and generates $52.16 million in revenue each year. The biopharmaceutical company earns $-67,210,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis.

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The official website for the company is www.ardelyx.com. The biopharmaceutical company can be reached via phone at (510) 745-1700, via email at investor@ardelyx.com, or via fax at 510-745-0493.